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ABSTRACT 
Background and Objective: Premenstrual syndrome (PMS) refers to a range of physical and psychological 
symptoms which regularly occur during the luteal phase of a menstrual cycle and disappear short after menstruation 
starts. Considering the negative effects of PMS on women’s daily life, various treatments have been developed to 
alleviate its symptoms. Vitamin B6 is one of the complementary therapies used to treat PMS. The present meta-
analysis aimed to investigate the effects of vitamin B6 on PMS.  
Methodology: Different databases including PubMed, ISI, Scopus, SID, Magiran, Science Direct, and Medlib were 
searched to identify studies addressing the effects of vitamin B6 on PMS. The relevant data obtained from these 
papers were analyzed by a random-effects model. Data were analyzed using R Ver. 3.2.3 Software and STATA. 
Results: There were significant reductions in the mean scores of PMS after treatment with vitamin B6 compare to 
control groups. Moreover, the mean PMS scores of the two groups were also significantly different after the 
treatment. The mean difference between the two groups was -1.19 [95% CI: -1.94,-0.44; P = 0.002]. Significant 
reductions were also observed in physical symptoms (P = 0.006) and psychological symptoms (P < 0.001) of PMS 
after the intervention. 
Conclusion: The results of our meta-analysis confirmed vitamin B6 as a beneficial, inexpensive, and effective 
treatment for PMS symptoms. Therefore, the administration of this treatment option will enable midwives to achieve 
the important goal of reducing PMS symptoms. 
KEY WORDS: premenstrual syndrome, physical symptoms, psychological symptoms, vitamin B6, female 
INTRODUCTION 
 Premenstrual syndrome (PMS) refers to a range of physical and psychological (emotional and behavioral) 
symptoms which can negatively affect the daily lives of women of the reproductive age during the luteal phase of 
their menstrual cycle. The symptoms of PMS may vary in different women but generally include depression, stress, 
mood swings, crying spells, irritability, anger, confusion, sleep disorders, clumsiness, social withdrawal, fatigue, 
abdominal cramping, breast tenderness, headache, stomachache, back pain, food cravings, bloating, and changes in 
libido. Such symptoms may occur in 10%-98% of women. In addition to the assessment tool used, the ethnicity, 
socioeconomic status, education level, lifestyle, and menstrual cycle characteristics of the studied population, as well 
as the use of hormonal contraceptives by the evaluated women, may affect the incidence of PMS. The high prevalence 
of PMS and its negative effects on women’s daily activities highlight the need for effective treatment. Therefore, a 
variety of treatment options, including antidepressants, anxiolytics, hormonal agents, serotonin reuptake inhibitors 
(SSRIs) such as fluoxetine, nutritional supplements (e.g. calcium, magnesium, and vitamins), and herbal medicines, 
have been suggested to reduce the symptoms of PMS.  
 Pyridoxine (vitamin B6) is also commonly used in thetreatment of PMS. Although this vitamin was initially 
believed to treat PMS by correcting impaired estrogen metabolism, its role in regulating brain monoamine production 
has been recently discussed. As an immediate precursor of serotonin and dopamine, vitamin B6 can alleviate PMS 
symptoms through its role in the production of prostaglandin and fatty acids. Moreover, vitamin B6 deficiency will 
reduce dopamine levels in kidneys. The consequent increment in sodium excretion will result in water retention and 
cause various symptoms such as swelling in extremities, edema, and abdominal and chest discomfort. Since a meta-
analysis is warranted to clarify the role of vitamin B6 in the treatment of PMS, the present study provided a systematic 
review and meta-analysis of the effectiveness of vitamin B6 in reducing PMS symptoms. 
Methods 
Search method: National and international databases, including Iranmedex, SID, Magiran, Irandoc, and Medlib in 
Persian and PubMed/Medline, Scopus, and ISI Web of Knowledge in English, were systematically searched using a 
number of keywords. The selected keywords were premenstrual syndrome, physical symptoms, psychological 
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symptoms, treatments, pyridoxine (vitamin B6), and their equivalents in Persian. All papers with the selected 
keywords in their titles or abstracts were included in the initial list and other unrelated articles were eliminated. We 
also searched bibliographies of retrieved articles for additional references. In addition, the references from selected 
articles were examined as a further search tool. Relevant trials noted in the reference lists of each selected article 
were also evaluated for inclusion.  
Inclusion and exclusion criteria: All original articles presenting case-control studies on the effects of vitamin B6 
on the severity of PMS symptoms were considered. When necessary, authors were contacted for additional 
information. Meta-analyses and systematic reviews were not included. Studies were excluded if they were in 
languages other than English or Persian, provided insufficient data, used a design other than the case-control design, 
and were a duplicate publication of another study. 
Data extraction: For all studies, the following data were extracted: first author, year of publication, location, sample 
size, sample age, and PMS scores, as well as physical and psychological symptoms, before and after the intervention 
in the vitamin b6 and placebo groups. Two of the authors independently reviewed the abstracts and full articles and 
resolved the cases of disagreement in a joint meeting. The data were entered into data collection forms and entered 
into Microsoft Excel. 
Data synthesis and analysis: Studies were combined based on the sample size, mean, and standard deviation. The 
difference between the PMS score in case and control groups divided to standard erroe of two groups was difened as 
standard mean difference(SMD). The Cochran’s Q, meta-regression and I2 were used as measures of heterogeneity 
of the studies. Considering the significant heterogeneity of the studies, the random effects model was applied. The 
additive method was used to poolded P-values of physical and psychological symptoms in that respect. 
 Funnel plots and Egger test were used to examine publication bias. P-values less than 0.05 were considered 
as significant in heterogeneity tests. Sensitivity analyses were pre-specified. Statistical analyses were performed 
using R Software (version 3.2.1) and STATA (version 10). 
Results 
 A total of 45 potentially suitable articles were identified during the initial search. In a secondary screening, 
six papers were excluded based on title and abstract evaluation and four others were excluded since they were 
duplicates of other research. Therefore, 35 articles were retained for detailed full-text evaluation. After full-text 
evaluation, we excluded another 23 articles (Of these, six were excluded because they did not include a placebo 
group, five were retrospective and review studies, twelve presented qualitative and defective quantitative data that 
could not be analyzed); all of these papers were withdrawn (Figure 1). Finally, 12 relevant papers were identified. 
The characteristics of the 12 studies included in this meta-analysis are summarized in Table 1. 
 Considering all the included studies, the total number of people in the intervention (vitamin B6) and placebo 
groups was 586 and 602, respectively. The mean age of the intervention and placebo groups was 27.77 ± 2.3 and 
27.21 ± 2.1 years, respectively and there was no significance differences between the two groups in this respect. The 
mean difference in age was 0.41 [95% CI:  - 0.04,0.33; P =0.419  (Table 1). 
 Table 2 presents the mean scores of PMS before and after the intervention in each group. As seen, the 
intervention and control groups had no significant differences in the mean scores of PMS symptoms before treatment. 
The SMD in the scores of the two groups was -0.13 [95% CI: -0.34,0.09; P = 0.254] (Figure 2). However, there was 
a significant difference in the SMD of PMS before and after treatment in each group. The SMD was -0.85 [95% CI: 
-1.48,-0.23; P = 0.008] in the control group and -1.76 [95% CI: -2.48,-1.04; P < 0.001] in intervention group. 
Moreover, a significant difference in PMS scores was observed between the intervention and control groups after 
the treatment. The SMD was -1.19 [95% CI: -1.94,-0.44; P = 0.002] (Figure 3). 
 
Figure.1.The flowchart of article selection for final analysis 
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Table.1.The characteristics of the selected studies 
N- 
Vitamin 
B6 
N-
Placebo 
Mean age SMD(95% CI) 
 
SMD Dose 
Vitamin B6 Placebo Lower Upper 
42 42 28.71 ± 5.37 28.03 ± 
5.02 
-0.30 0.56 0.13 250 mg  daily over 2 menstrual cycles 
20 20 28.01 ±5.08 28 ± 5.17 -0.62 0.62 0.00 100 mg daily over 3 menstrual cycles 
16 16 - - - - - 50 mg daily over 3 menstrual cycles 
29 26 28.1 ± 6.5 27.7 ± 6.6 -0.47 0.59 0.06 150 mg daily over 2 menstrual cycles 
46 48 - - - - - 80 mg daily over 2 menstrual cycles 
30 30 - 
 
- - - - 300 mg daily over 3 menstrual cycles 
31 31 21.1 ± 0.6 20.7 ± 0.5 0.21 1.24 0.72 40 mg daily over 2 menstrual cycles 
204 230 33.4 ± 7.9 33.3 ± 7.4 -0.18 0.20 0.01 100 mg daily over 3 menstrual cycles 
31 31 23.19 ± 2.1 22.4 ± 1.9 -0.11 0.90 0.39 40 mg daily over 3 menstrual cycles 
40 40 32 ± 6.5 32 ± 6.1 -0.44 0.44 0.00 50 mg daily over 1 menstrual cycles 
52 40 24.5 ± 2.3 23 ± 2.1 0.25 1.10 0.68 200 mg  daily over 2 menstrual cycles 
46 48 31.4 ± 6.2 30.2 ± 5.5 -0.20 0.61 0.21 80 mg  daily over3 menstrual cycles 
SMD: standard mean difference, CI: confidence interval 
 
Table.2.Scores of premenstrual syndrome before and after the intervention in vitamin B6 and placebo 
groups 
Scores of PMS 
Before the 
intervention 
SMD (95% 
CI) 
 
 
SMD 
Scores of PMS after 
the intervention 
SMD (95% CI) 
 
SMD 
Vitamin 
B6 
Placebo Lower uppe
r 
Vitamin 
B6 
Placebo Lower Upper 
36.51 ± 
7.06 
35.80 ± 
6.76 
-0.33 0.53 -0.10 22.84 ± 
6.76 
28.41 ± 
4.33 
-1.43 -0.53 -0.98 
30.15 ± 
10.71 
31.35 ± 
7.67 
-0.75 0.49 -0.13 10.1 ± 4.79 29.2 ± 
10.31 
-3.19 -1.56 -2.38 
- - - - - 10.39 ± 
1.91 
17.74 ± 
1.89 
-2.79 -1.09 -1.94 
18.74 ± 
4.90 
21.35 ± 
6.85 
-0.89 0.09 -0.44 16.67 ± 
4.37 
17.79 ± 
5.13 
-0.77 0.30 -0.24 
40 ± 8.10 40.3 ± 7.91 -0.54 0.47 -0.04 21.90 ± 
12.60 
21.6 ± 11 -0.48 
 
0.53 0.03 
41.23 ± 
9.03 
43.18 ± 
10.05 
-0.61 0.20 -0.20 21.25 ± 
8.15 
40.63 ± 
12.18 
-2.35 -1.38 -1.86 
SMD: standard mean difference, CI: confidence interval 
 
 
Figure.2.The results of meta-analysis of mean premenstrual syndrome scores before the intervention in vitamin B6 
and placebo groups. The squares represent the effect estimates and their 95% confidence intervals indicated by 
individual studies. Square sizes are proportional to the weight assigned to the study in the meta-analysis. Diamond 
shows poold results of studies. In this chart, studies are displayed in the order of the year of publication and authors’ 
names based on a random effects model 
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Figure.3.The results of meta-analysis of mean premenstrual syndrome scores after the intervention in vitamin B6 
and placebo groups. The squares represent the effect estimates and their 95% confidence intervals indicated by 
individual studies. Square sizes are proportional to the weight assigned to the study in the meta-analysis. Diamond 
shows poold results of studies .In this chart, studies are displayed in the order of the year of publication and authors’ 
names based on a random effects model 
Tables 3 and 4 show the mean scores of physical and psychological symptoms of PMS before and after the 
intervention in each group. As seen, vitamin B6 and placebo groups had a significant difference in physical symptoms 
of PMS after the intervention (P = 0.006; Figure 4). A similar significant difference was also observed between the 
two groups in terms of psychological symptoms of PMS after the intervention (P < 0.001; Figure 5). 
The results of meta-analysis of physical symptoms of premenstrual syndrome after the intervention in 
vitamin B6 and placebo groups accoding to combine p-vale of 11 studies using edgington additive models show that, 
there was significance difference between two groups(P=.0069). 
Table.3.Physical symptoms of premenopausal syndrome before and after the intervention in vitamin B6 and 
placebo groups 
Physical symptoms Scores of  physical symptoms   SMD (95% CI) 
 
SMD P value 
Vitamin B6 Placebo Lower Upper 
Mean changes 
before and after 
the intervention 
-12.8± 19.25 -2.5± 16.97 -01.00 -0.13 -0.56 0.011 
-0.54± 0.63 -0.33± 0.7 -0.72 0.09 -0.31 0.129 
Mean scores after 
the intervention 
8.69± 1.24 8.97± 1.08 -0.94 0.45 -0.24 0.497 
2.7± 0.74 2.97± 0.95 -0.85 0.21 -0.32 0.24 
6.16± 1.71 7.35± 1.6 -1.23 -0.20 -0.72 0.006 
18.7± 5.9 19.3± 6.3 -0.54 0.34 -0.10 0.6 
98.91±26.14 96.18±19.7 -0.29 0.52 0.12 0.567 
Number of cases 
after the 
intervention 
14/30 13/30 0.62 1.98 1.08 0.795 
14/31 6/31 1.03 5.28 2.33 0.042 
105/204 105/230 0.93 1.37 1.13 0.226 
12/52 20/40 0.26 0.83 0.46 0.010 
Table.4.Psychological symptoms of premenstrual syndrome before and after the intervention in vitamin B6 
and placebo groups 
Psychological 
symptoms 
Scores of  psychological 
symptoms 
SMD (95% CI) 
 
SMD P value 
Vitamin B6 Placebo Lower Upper 
Mean changes 
before and after the 
intervention 
-16.32± 17.2 -8.2±18.8 -0.94 -0.07 -0.50 0.023 
-1.26± 1.91 -0.6± 1.78 -0.77 0.05 -0.36 0.085 
Mean scores after 
the intervention 
3.96± 0.9 7.06± 1.29 -3.78 -1.80 -2.79 0.000 
2.1±0.47 2.45±0.8 -1.08 -0.00 -0.54 0.049 
11.97± 2.33 10.47± 1.67 0.22 1.26 0.74 0.005 
21.2± 6.7 17.6± 5.1 0.16 1.05 0.60 0.008 
12.16±24.96 136.8±21.14 -6.28 -4.52 -5.40 0.000 
Number of cases 
after the 
intervention 
14/30 14/30 0.58 1.72 1.00 1.00 
21/31 10/31 1.19 3.69 2.10 0.010 
115/204 119/230 0.92 1.30 1.09 0.333 
7/52 13/40 0.18 0.94 0.41 0.035 
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The results of meta-analysis of psychological symptoms of premenstrual syndrome after the intervention in 
vitamin B6 and placebo groups, accoding to pooled  p-vale of 11 studies using edgington normal models show that, 
there was significance difference between two groups(P=.000)  
Figure 4 presents the funnel plot of the included trials. Regression analysis of this plot indicated no 
significant asymmetry(P=.389) and thus no evidence of bias. In fact, most studies were located inside the funnel plot, 
i.e. the results of most relevant studies performed were included in the analysis (Figure 6).  
 
Figure.4.Funnel plot for publication bias in the risk difference (RD) analysis 
Discussion  
Pyridoxine, or vitamin B6, is one of the most widely used and probably the most controversial treatment for 
PMS. In a survey of 658 women with PMS, Corney and Stanton found that vitamin B6 was the most common 
treatment for PMS. According to the National Association for Premenstrual Syndrome in UK, 68% of general 
practitioners prescribed vitamin B6 for premenstrual symptoms. In a review study, Wyatt et al. confirmed vitamin 
B6 as the first choice over-the-counter treatment for many women with PMS. The UK Department of Health then 
offered some plans to restrict the dosage available because of potential neurotoxic effects at very high doses. As a 
result, vitamin B6 prescriptions dropped markedly from 22% in 1993 to 11% in 1997 and 1998. Wyatt et al. 
concluded that the most effective management method for PMS symptoms cannot be identified unless evidence for 
all possible treatments are assessed by critical appraisal and meta-analysis. Therefore, we conducted a systematic 
review and meta-analysis to evaluate the effects of vitamin B6 on PMS symptoms. We selected studies which had 
compared the mean changes in PMS scores following the use of vitamin B6 and placebo. The obtained statistical 
results suggested the significant positive effect of vitamin B6 on reducing PMS symptoms. In a review study in 2002, 
The low quality of studies included in the meta-analysis and enormous inhomogeneity in their results might have 
been responsible for the inconsistency between our findings and the results of the mentioned studies. Furthermore, 
the difference in selection criteria of studies, analysis methods, and results could also justify the observed 
discrepancies. 
Our findings highlighted the positive effects of vitamin B6 on reducing the psychological symptoms of PMS. 
Likewise, a meta-analysis conducted by Wyatt et al. demonstrated the beneficial effects of vitamin B6 in the 
treatment of depression. Similarly, Salehi et al. indicated the efficacy of daily consumption of pyridoxine (200 mg) 
in controlling the psychological symptoms of PMS, e.g. depression, anxiety, unrest, and sleepiness. Another study 
documented reductions in frustration, anger, mental pressure, social avoidance, increased appetite, and tachycardia 
following the daily consumption of vitamin B6 (40 mg). Maroufi et al. also confirmed the significant effects of 
vitamin B6 on alleviating the temperamental and behavioral symptoms of PMS. Ebrahimi et al. suggested vitamin 
B6 to effectively treat the psychological symptoms associated with depression and anxiety. Other studies have also 
reported similar results. Therefore, previous studies and the current meta-analysis support this the positive effects of 
pyridoxine, even in small doses, on reducing the psychological symptoms of PMS. 
Pyridoxine is a cofactor in the synthesis of neurotransmitters and an immediate precursor of serotonin and 
dopamine. It is also involved in gamma-aminobutyric acid (GABA) synthesis and enzymatic steps of tryptophan and 
tyrosine metabolism. Its deficiency may, hence, lead to reduced concentrations of noradrenaline and serotonin. 
Vitamin B6 is claimed to be associated with psychological symptoms of PMS. Low levels of vitamin B6 increase 
prolactin levels and results in more psychological symptoms during the premenstrual period. These symptoms may 
also be a consequence of a reduction in the metabolism of tryptophan to 5-hydroxytryptamine (5HT). On the other 
hand, imbalances in the levels of steroid hormones may cause a relative pyridoxine deficiency. The mentioned 
mechanisms can justify the findings of previous research and the present study regarding the role of vitamin B6 in 
alleviating the psychological symptoms of PMS.   
The results of the present study showed that daily consumption of vitamin B6 was significantly more 
effective than placebo in improving the physical signs and symptoms of PMS. Dolatian et al. compared a daily dose 
of 40 mg of vitamin B6 with placebo and reported vitamin B6 to significantly reduce the physical symptoms of PMS, 
e.g. abdominal pain, backache, muscular pain, chest pain, and allergy. Likewise, Salehi et al. highlighted the 
beneficial effects of daily intake of pyridoxine (200 mg) on reducing breast sensitivity (a somatic sign of PMS). 
Begg's funnel plot with pseudo 95% confidence limits
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D
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Some other case-control studies have also confirmed considerable reductions in physical symptoms of PMS 
following the consumption of vitamin B6. In contrast, a number of studies have rejected the role of vitamin B6 in 
improving physical symptoms of PMS. 
Researchers believe that vitamin B6 deficiency decreases dopamine in the kidneys. The consequent increase 
in sodium excretion will in turn cause water retention and lead to the physical symptoms of PMS such as swelling in 
extremities, edema, and abdominal and chest discomfort. Therefore, vitamin B6 consumption should be able to 
alleviate the physical and psychological symptoms of PMS. Studies have also suggested reductions in red blood cell 
counts to cause PMS through decreasing brain dopamine and increasing aldosterone. As mentioned earlier, these 
problems can be treated by using pyridoxine. Considering the role of pyridoxine in water metabolism, regulation of 
adrenal hormones, and synthesis of some amino acids, as cofactors, consuming vitamin B6 during the whole 
menstrual cycle can reduce the general symptoms of PMS. 
Another finding of the present study was the effect of placebo on reducing PMS symptoms. Although this 
reduction was significantly lower compared to the intervention group, placebo could exert some positive effects. 
Similarly, many studies on PMS have observed reductions in PMS symptoms in control groups (with or without the 
use of placebo). Apparently, receiving attention could positively affect the mental status of the participants and 
facilitate the treatment of PMS .  
Previous research on the dosage of vitamin B6 has reported contradictory results. While some studies have 
emphasized the need for high doses of vitamin B6 over a long period of time (during the whole menstrual cycle), 
some others did not detect any significant effects on PMS symptoms even with high doses of vitamin B6. Low doses 
of vitamin B6 have also been reported ineffective by some studies. In a study on Iranian women, Ebrahimi et al. 
showed that consuming 250 mg of vitamin B6 per day for two months significantly reduced the general symptoms 
of PMS as compared to placebo. In India, Sharma et al. compared vitamin B6 and placebo and concluded that daily 
consumption of 100 mg of vitamin B6 for three months significantly improved PMS symptoms. In the US, Doll et 
al. highlighted the beneficial effects of daily consumption of vitamin B6 (100 mg) for three months. A meta-analysis 
by Wyatt et al. confirmed the mentioned positive effects. However, based on the analysis of previous studies in the 
current meta-analysis, the efficiency of vitamin B6 does not depend on its dosage. No evidence has been reported 
about the toxicity or side effects of vitamin B6. This might have been due to the low dosage of vitamin B6 in most 
studies evaluated by the present meta-analysis.   
Our meta-analysis had several limitations. First, insufficient information about vitamin B6 toxicity and side 
effects prevented us from the evaluation of such cases. Moreover, some included studies did not enjoy acceptable 
quality or presented defective quantitative data that could not be included in meta-analysis. Furthermore, since the 
selected studies were quite heterogeneous in terms of their inclusion and exclusion criteria, the dose and duration of 
treatment, and the outcome measures examined, the interpretation of the findings was difficult. Finally, some studies 
associated with PMS were not accessible. 
CONCLUSION 
Considering the importance of PMS and the numerous effects it has on women’s lives (and thus the society), 
the diagnosis and treatment of this syndrome should be prioritized. Optimal management of PMS requires a 
systematic approach to find the most effective drug with the least side effects to prevent the occurrence of the 
syndrome. The results of our meta-analysis revealed that using vitamin B6 could reduce the overall symptoms of 
PMS. No conclusive evidence of vitamin B6 toxicity was reported and there seems to be no dose-related response to 
treatment. In conclusion, vitamin B6 is a beneficial, inexpensive, and effective treatment for the symptoms of PMS. 
Although women with PMS can be encouraged to take pyridoxine, further studies are warranted to confirm vitamin 
B6 as a safe and effective treatment for PMS. 
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